Skip to main content
Premium Trial:

Request an Annual Quote

UK's Precision Medicine Catapult Plans Six Centers of Excellence

NEW YORK (GenomeWeb) – The UK's Precision Medicine Catapult today announced the initial locations for its six regional centers of excellence: Belfast, Cardiff, Glasgow, Leeds, Manchester, and Oxford.

The six centers will make up a nationwide network coordinated from Cambridge, with each center acting as a regional hub for precision medicine programs. Each center will establish a physical presence and recruit locally to build teams of experts to collaborate with government, academia, and local healthcare systems and companies.

The Cambridge headquarters will offer expertise in core areas such as data analytics, clinical trials, regulatory affairs, healthcare economics, and business services.

"Project development work has been ongoing across the UK and we will be launching offices and related programs over the coming months," Precision Medicine Catapult CEO John McKinley said in a statement.

The network, launched in July, is partially supported by Innovate UK, a government-funded agency.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.